{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T12:24:24Z","timestamp":1775651064114,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-04975-6","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T20:23:31Z","timestamp":1715631811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Conservative treatment of Peyronie\u2019s disease: a guide"],"prefix":"10.1007","volume":"42","author":[{"given":"Marco","family":"Cosentino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Di Nauta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Boeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giordana","family":"Ferraioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpaolo","family":"Lucignani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ricapito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Gadda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Iafrate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Dal Moro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Ruiz-Casta\u00f1e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Bettocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Montanari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Sofikitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"4975_CR1","first-page":"318","volume":"1","author":"FG De la Peyronie","year":"1743","unstructured":"De la Peyronie FG (1743) Sur quelques obstacles qui s\u2019opposent a l\u2019\u00e9jaculation naturelle de la semence. M\u00e9m Acad Roy Chir 1:318\u2013333","journal-title":"M\u00e9m Acad Roy Chir"},{"key":"4975_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1743-6109.2012.03003.x","volume":"10","author":"L Levine","year":"2013","unstructured":"Levine L, Burnett AL (2013) Standard operating procedures for Peyronie\u2019s disease. J Sex Med 10:230\u2013244","journal-title":"J Sex Med"},{"key":"4975_CR3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jsxm.2016.04.062","volume":"13","author":"E Chung","year":"2016","unstructured":"Chung E, Ralph D, Kagiouglu A, Garaffa G, Shamsodini A, Boivalacqua T, Glina S, Hakim L, Sadeghi-Nejad H, Broderick G (2016) Evidence-based management guidelines on Peyronie\u2019s disease. J Sex Med 13:905\u2013923","journal-title":"J Sex Med"},{"key":"4975_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/282503","author":"DB Dibenedetti","year":"2011","unstructured":"Dibenedetti DB, Nguyen D, Zografos Ziemiecki R, Zhou X (2011) A population based study on Peyronie\u2019s disease: prevalence and treatment patterns in the United States. Adv Urol. https:\/\/doi.org\/10.1155\/2011\/282503","journal-title":"Adv Urol"},{"issue":"6","key":"4975_CR5","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41443-020-0324-7","volume":"33","author":"E Pozzi","year":"2021","unstructured":"Pozzi E, Capogrosso P, Boeri L, Cazzaniga W, Matloob R, Ventimiglia E, Oreggia D, Schifano N, Candela L, Abbate C, Montorsi F, Salonia A (2021) Trends in reported male sexual dysfunction over the past decade: an evolving landscape. Int J Impot Res 33(6):596\u2013602. https:\/\/doi.org\/10.1038\/s41443-020-0324-7. (Epub 2020 Jul 1)","journal-title":"Int J Impot Res"},{"key":"4975_CR6","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/ajcp\/45.6.670","volume":"45","author":"BH Smith","year":"1966","unstructured":"Smith BH (1966) Peyronie\u2019s disease. Am J Clin Pathol 45:670\u2013678","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"4975_CR7","first-page":"84","volume":"2008","author":"R Rosen","year":"1977","unstructured":"Rosen R, Catania J, Lue T, Althof S, Henne J, Hellstrom W et al (1977) Impact of Peyronie\u2019s disease on sexual and psychological functioning: qualitative findings in patients and controls. J Sex Med 2008(5):84","journal-title":"J Sex Med"},{"key":"4975_CR8","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/S0022-5347(17)52339-3","volume":"129","author":"M Gelbard","year":"1983","unstructured":"Gelbard M, Lindner A, Chvapil M et al (1983) Topical beta-aminopropionitrile in the treatment of Peyronie\u2019s disease. J Urol 129:746","journal-title":"J Urol"},{"key":"4975_CR9","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.eururo.2005.04.011","volume":"48","author":"CR Riedl","year":"2005","unstructured":"Riedl CR, Sternig P, Gall\u00e9 G et al (2005) Liposomal recombinant human superoxide dismutase for the treatment of Peyronie\u2019s disease: a randomized placebo-controlled double blind prospective clinical study. Eur Urol 48:656\u2013661","journal-title":"Eur Urol"},{"issue":"2","key":"4975_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/ijir.2015.22","volume":"28","author":"J Twidwell","year":"2016","unstructured":"Twidwell J, Levine L (2016) Topical treatment for acute phase Peyronie\u2019s disease utilizing a new gel, H-100: a randomized, prospective, placebo- controlled pilot study. Int J Impot Res 28(2):41","journal-title":"Int J Impot Res"},{"key":"4975_CR11","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1016\/S0022-5347(05)64173-0","volume":"168","author":"DJ Martin","year":"2002","unstructured":"Martin DJ, Badwan K, Parker M, Mulhall JP (2002) Transdermal application of Verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 168:2483\u20132485","journal-title":"J Urol"},{"issue":"2","key":"4975_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1743-6109.2006.00417.x","volume":"4","author":"WP Fitch III","year":"2007","unstructured":"Fitch WP III, Easterling WJ, Talbert RL et al (2007) Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie\u2019s disease \u2013 a placebo-controlled pilot study. J Sex Med 4(2):477\u2013484","journal-title":"J Sex Med"},{"issue":"4","key":"4975_CR13","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/01.ju.0000116450.82816.2c","volume":"171","author":"SM Di Stasi","year":"2004","unstructured":"Di Stasi SM, Giannantoni A, Stephen RL et al (2004) A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie\u2019s disease. J Urol 171(4):1605\u20131608","journal-title":"J Urol"},{"issue":"2","key":"4975_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/01.ju.0000108060.30363.8d","volume":"171","author":"EW Hauck","year":"2004","unstructured":"Hauck EW, Mueller UO, Bschleipfer T, Schmelz HU, Diemer T, Weidner W (2004) Extracorporeal shock wave therapy for Peyronie\u2019s disease: exploratory meta-analysis of clinical trials. J Urol 171(2):740\u2013745","journal-title":"J Urol"},{"key":"4975_CR15","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1111\/jsm.12275","volume":"10","author":"G Hatzichristodoulou","year":"2013","unstructured":"Hatzichristodoulou G et al (2013) Extracorporeal shock wave therapy in Peyronie\u2019s disease: results of a placebo- controlled, prospective, randomized, single blind study. J Sex Med 10:2815\u20132821","journal-title":"J Sex Med"},{"key":"4975_CR16","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021. ISBN 978-94-92671-13-4"},{"key":"4975_CR17","doi-asserted-by":"crossref","unstructured":"Pietsch G, Anzeneder T, Bruckbauer H et al. Superficial radiation therapy in Peyronie\u2019s disease: an effective and well-tolerated therapy. Adv Radiat Oncol. 2018;3(4):548\u2013551. Published 2018 Aug 7","DOI":"10.1016\/j.adro.2018.07.009"},{"key":"4975_CR18","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1743-6109.2008.01108.x","volume":"6","author":"P Gontero","year":"2009","unstructured":"Gontero P et al (2009) Use of penile extender device in the treatment of penile curvature as a result of Peyronie\u2019s disease. Results of a phase II prospective study. J Sex Med 6:558\u2013566","journal-title":"J Sex Med"},{"key":"4975_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/JU.0000000000000245","volume":"202","author":"M Ziegelmann","year":"2019","unstructured":"Ziegelmann M et al (2019) Outcomes of a novel penile traction device in men with Peyronie\u2019s disease: a randomized, single-blind, controlled trial. J Urol 202:599","journal-title":"J Urol"},{"issue":"1","key":"4975_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2164\/jandrol.110.010561","volume":"33","author":"AJ Schaeffer","year":"2012","unstructured":"Schaeffer AJ, Burnett AL (2012) Nonsurgical interventions for Peyronie disease: 2011 update. J Androl 33(1):3\u201314. https:\/\/doi.org\/10.2164\/jandrol.110.010561. (Epub 2011 Feb 24. PMID: 21350241)","journal-title":"J Androl"},{"issue":"3","key":"4975_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1464-410X.2006.05955.x","volume":"97","author":"MG Ferrini","year":"2006","unstructured":"Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF (2006) Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie\u2019s disease. BJU Int 97(3):625\u2013633. https:\/\/doi.org\/10.1111\/j.1464-410X.2006.05955.x. (PMID: 16469038)","journal-title":"BJU Int"},{"issue":"10","key":"4975_CR22","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.jsxm.2020.06.022","volume":"17","author":"MM Ilg","year":"2020","unstructured":"Ilg MM, Stafford SJ, Mateus M, Bustin SA, Carpenter MJ, Muneer A, Bivalacqua TJ, Ralph DJ, Cellek S (2020) Phosphodiesterase type 5 inhibitors and selective estrogen receptor modulators can prevent but not reverse myofibroblast transformation in Peyronie\u2019s disease. J Sex Med 17(10):1848\u20131864. https:\/\/doi.org\/10.1016\/j.jsxm.2020.06.022. (Epub 2020 Aug 5. PMID: 32771352)","journal-title":"J Sex Med"},{"issue":"3","key":"4975_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/sj.ijir.3900519","volume":"12","author":"A Kadioglu","year":"2000","unstructured":"Kadioglu A, Tefekli A, K\u00f6ksal T, Usta M, Erol H (2000) Treatment of Peyronie\u2019s disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res 12(3):169\u2013175. https:\/\/doi.org\/10.1038\/sj.ijir.3900519. (PMID: 11045911)","journal-title":"Int J Impot Res"},{"issue":"3","key":"4975_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/sj.ijir.3901185","volume":"16","author":"MR Safarinejad","year":"2004","unstructured":"Safarinejad MR (2004) Therapeutic effects of colchicine in the management of Peyronie\u2019s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 16(3):238\u2013243. https:\/\/doi.org\/10.1038\/sj.ijir.3901185. (PMID: 14973528)","journal-title":"Int J Impot Res"},{"issue":"5","key":"4975_CR25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/ijir.2010.20","volume":"22","author":"MR Safarinejad","year":"2010","unstructured":"Safarinejad MR (2010) Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie\u2019s disease: a double-blind, placebo-controlled randomized study. Int J Impot Res 22(5):298\u2013309. https:\/\/doi.org\/10.1038\/ijir.2010.20. (Epub 2010 Aug 19. PMID: 20720560)","journal-title":"Int J Impot Res"},{"issue":"4","key":"4975_CR26","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1152\/physrev.1983.63.4.1420","volume":"63","author":"J Bremer","year":"1983","unstructured":"Bremer J (1983) Carnitine\u2013metabolism and functions. Physiol Rev 63(4):1420\u20131480. https:\/\/doi.org\/10.1152\/physrev.1983.63.4.1420. (PMID: 6361812)","journal-title":"Physiol Rev"},{"issue":"1","key":"4975_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1046\/j.1464-410x.2001.02241.x","volume":"88","author":"G Biagiotti","year":"2001","unstructured":"Biagiotti G, Cavallini G (2001) Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie\u2019s disease: a preliminary report. BJU Int 88(1):63\u201367. https:\/\/doi.org\/10.1046\/j.1464-410x.2001.02241.x. (PMID: 11446848)","journal-title":"BJU Int"},{"key":"4975_CR28","doi-asserted-by":"publisher","unstructured":"Safarinejad MR, Hosseini SY, Kolahi AA (2007) Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie\u2019s disease: a double-blind, placebo controlled, randomized study. J Urol. 178(4 Pt 1):1398\u20131403; discussion 1403. https:\/\/doi.org\/10.1016\/j.juro.2007.05.162. Epub 2007 Aug 16. PMID: 17706714","DOI":"10.1016\/j.juro.2007.05.162"},{"issue":"6","key":"4975_CR29","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1111\/j.1743-6109.2009.01235.x","volume":"6","author":"MR Safarinejad","year":"2009","unstructured":"Safarinejad MR (2009) RETRACTED: efficacy and safety of omega-3 for treatment of early-stage Peyronie\u2019s disease: a prospective, randomized, double-blind placebo-controlled study. J Sex Med 6(6):1743\u20131754. https:\/\/doi.org\/10.1111\/j.1743-6109.2009.01235.x. (Epub 2009 Apr 23. PMID: 19453924)","journal-title":"J Sex Med"},{"issue":"6","key":"4975_CR30","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1111\/j.1743-6109.2010.01790.x","volume":"7","author":"AW Shindel","year":"2010","unstructured":"Shindel AW, Lin G, Ning H, Banie L, Huang YC, Liu G, Lin CS, Lue TF (2010) Pentoxifylline attenuates transforming growth factor-\u03b21-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J Sex Med 7(6):2077\u20132085. https:\/\/doi.org\/10.1111\/j.1743-6109.2010.01790.x. (Epub 2010 Mar 30. PMID: 20367772; PMCID: PMC3543151)","journal-title":"J Sex Med"},{"issue":"2","key":"4975_CR31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/gut.50.2.241","volume":"50","author":"C Raetsch","year":"2002","unstructured":"Raetsch C, Jia JD, Boigk G, Bauer M, Hahn EG, Riecken EO, Schuppan D (2002) Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut 50(2):241\u2013247. https:\/\/doi.org\/10.1136\/gut.50.2.241. (PMID: 11788567; PMCID: PMC1773098)","journal-title":"Gut"},{"issue":"1","key":"4975_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.5534\/wjmh.2016.34.1.40","volume":"34","author":"TY Park","year":"2016","unstructured":"Park TY, Jeong HG, Park JJ, Chae JY, Kim JW, Oh MM, Park HS, Kim JJ, du Moon G (2016) The efficacy of medical treatment of Peyronie\u2019s disease: potassium para-aminobenzoate monotherapy vs. combination therapy with tamoxifen, L-carnitine, and phosphodiesterase type 5 inhibitor. World J Mens Health. 34(1):40\u201346. https:\/\/doi.org\/10.5534\/wjmh.2016.34.1.40. (Epub 2016 Apr 30. PMID: 27169128; PMCID: PMC4853769)","journal-title":"World J Mens Health."},{"issue":"2","key":"4975_CR33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/tcrm.2007.3.2.213","volume":"3","author":"JP Armand","year":"2007","unstructured":"Armand JP, Ribrag V, Harrousseau JL, Abrey L (2007) Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Ther Clin Risk Manag 3(2):213\u2013224. https:\/\/doi.org\/10.2147\/tcrm.2007.3.2.213. (PMID: 18360630; PMCID: PMC1936303)","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"4975_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/bjc.1990.307","volume":"62","author":"AA Colletta","year":"1990","unstructured":"Colletta AA, Wakefield LM, Howell FV, van Roozendaal KE, Danielpour D, Ebbs SR, Sporn MB, Baum M (1990) Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 62(3):405\u2013409. https:\/\/doi.org\/10.1038\/bjc.1990.307. (PMID: 1698443; PMCID: PMC1971440)","journal-title":"Br J Cancer"},{"issue":"6","key":"4975_CR35","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/s0022-5347(05)68087-1","volume":"162","author":"C Teloken","year":"1999","unstructured":"Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA (1999) Tamoxifen versus placebo in the treatment of Peyronie\u2019s disease. J Urol 162(6):2003\u20132005. https:\/\/doi.org\/10.1016\/s0022-5347(05)68087-1. (PMID: 10569556)","journal-title":"J Urol"},{"issue":"4","key":"4975_CR36","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/j.1743-6109.2007.00674.x","volume":"5","author":"AW Shindel","year":"2008","unstructured":"Shindel AW, Bullock TL, Brandes S (2008) Urologist practice patterns in the management of Peyronie\u2019s disease: a nationwide survey. J Sex Med 5(4):954\u2013964. https:\/\/doi.org\/10.1111\/j.1743-6109.2007.00674.x. (Epub 2007 Nov 27. PMID: 18042214)","journal-title":"J Sex Med"},{"issue":"2","key":"4975_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/s0022-5347(05)64691-5","volume":"168","author":"LA Levine","year":"2002","unstructured":"Levine LA, Goldman KE, Greenfield JM (2002) Experience with intraplaque injection of verapamil for Peyronie\u2019s disease. J Urol 168(2):621\u2013626. https:\/\/doi.org\/10.1016\/s0022-5347(05)64691-5","journal-title":"J Urol"},{"issue":"5","key":"4975_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/SJ.IJIR.3900874","volume":"14","author":"JP Mulhall","year":"2002","unstructured":"Mulhall JP, Anderson MS, Lubrano T, Shankey TV (2002) Peyronie\u2019s disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 14(5):397\u2013405. https:\/\/doi.org\/10.1038\/SJ.IJIR.3900874","journal-title":"Int J Impot Res"},{"issue":"1","key":"4975_CR39","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","volume":"176","author":"WJG Hellstrom","year":"2006","unstructured":"Hellstrom WJG, Kendirci M, Matern R et al (2006) Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon \u03b1-2b for minimally invasive treatment for Peyronie\u2019s disease. J Urol 176(1):394\u2013398. https:\/\/doi.org\/10.1016\/S0022-5347(06)00517-9","journal-title":"J Urol"},{"issue":"6","key":"4975_CR40","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/j.juro.2013.05.022","volume":"190","author":"LW Trost","year":"2013","unstructured":"Trost LW, Ates E, Powers M, Sikka S, Hellstrom WJG (2013) Outcomes of intralesional interferon-\u03b12B for the treatment of Peyronie disease. J Urol 190(6):2194\u20132199. https:\/\/doi.org\/10.1016\/j.juro.2013.05.022","journal-title":"J Urol"},{"issue":"6","key":"4975_CR41","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.juro.2015.06.096","volume":"194","author":"CA Stewart","year":"2015","unstructured":"Stewart CA, Yafi FA, Knoedler M et al (2015) Intralesional injection of interferon-\u03b12b improves penile curvature in men with Peyronie\u2019s disease independent of plaque location. J Urol 194(6):1704\u20131707. https:\/\/doi.org\/10.1016\/j.juro.2015.06.096","journal-title":"J Urol"},{"issue":"15","key":"4975_CR42","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.3390\/MOLECULES26154429","volume":"26","author":"AM Juncan","year":"2021","unstructured":"Juncan AM, Mois\u0103 DG, Santini A et al (2021) Advantages of hyaluronic acid and its combination with other bioactive ingredients in cosmeceuticals. Molecules 26(15):4429. https:\/\/doi.org\/10.3390\/MOLECULES26154429","journal-title":"Molecules"},{"issue":"10","key":"4975_CR43","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s11255-015-1074-1","volume":"47","author":"R Gennaro","year":"2015","unstructured":"Gennaro R, Barletta D, Paulis G (2015) Intralesional hyaluronic acid: an innovative treatment for Peyronie\u2019s disease. Int Urol Nephrol 47(10):1595\u20131602. https:\/\/doi.org\/10.1007\/s11255-015-1074-1","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"4975_CR44","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/j.esxm.2016.01.002","volume":"4","author":"A Zucchi","year":"2016","unstructured":"Zucchi A, Costantini E, Cai T et al (2016) Intralesional injection of hyaluronic acid in patients affected with Peyronie\u2019s disease: preliminary results from a prospective, multicenter, pilot study. Sex Med 4(2):e85\u2013e90. https:\/\/doi.org\/10.1016\/j.esxm.2016.01.002","journal-title":"Sex Med"},{"issue":"2","key":"4975_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5534\/wjmh.190108","volume":"38","author":"A Cocci","year":"2020","unstructured":"Cocci A, Di Maida F, Cito G et al (2020) Comparison of intralesional hyaluronic acid vs. verapamil for the treatment of acute phase Peyronie\u2019s disease: a prospective, open-label non-randomized clinical study. World J Mens Health 38(2):1\u20136. https:\/\/doi.org\/10.5534\/wjmh.190108","journal-title":"World J Mens Health"},{"issue":"2","key":"4975_CR46","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.22037\/UJ.V12I2.2894","volume":"12","author":"CA Mu\u00f1oz-Rangel","year":"2015","unstructured":"Mu\u00f1oz-Rangel CA, Fernandez-Vivar E, Ba\u00f1uelos-Gallo RA et al (2015) Minimally invasive therapy using intralesional onabotulinumtoxinA in Peyronie\u2019s disease. Urol J 12(2):2105\u20132110. https:\/\/doi.org\/10.22037\/UJ.V12I2.2894","journal-title":"Urol J"},{"key":"4975_CR47","unstructured":"Cipollone G, Nicolai M, Mastroprimiano G, Iantorno R, Longeri D, Tenaglia R (1998) Betamethasone versus placebo in Peyronie\u2019s disease [Article in Italian]. Arch Ital Urol Androl 70(4):165\u2013168. https:\/\/pubmed.ncbi.nlm.nih.gov\/9823662\/"},{"key":"4975_CR48","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.sxmr.2020.12.004","volume":"10","author":"MH Alkandari","year":"2021","unstructured":"Alkandari MH, Touma N, Carrier S (2021) Platelet-rich plasma injections for erectile dysfunction and Peyronie\u2019s disease: a systematic review of evidence. Sex Med Rev 10:341\u2013352","journal-title":"Sex Med Rev"},{"issue":"2","key":"4975_CR49","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000492755","volume":"102","author":"MG Culha","year":"2019","unstructured":"Culha MG, Erkan E, Cay T, Y\u00fcceta\u015f U (2019) The effect of platelet-rich plasma on Peyronie\u2019s disease in rat model. Urol Int 102(2):218\u2013223","journal-title":"Urol Int"},{"issue":"1","key":"4975_CR50","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2011","unstructured":"Gelbard M et al (2011) Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 190(1):199\u2013207","journal-title":"J Urol"},{"issue":"4","key":"4975_CR51","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bju.13096","volume":"116","author":"LI Lipshulz","year":"2015","unstructured":"Lipshulz LI et al (2015) Clinical efficacy of collagenase chlostridium histolyticum in the treatment of Peyronie\u2019s disease by subgroup: results from two large, double blind, randomized, placebo-controlled, phase III studies. BJU Int 116(4):650\u2013656","journal-title":"BJU Int"},{"issue":"2","key":"4975_CR52","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00345-019-02791-x","volume":"38","author":"FM El-Khatib","year":"2020","unstructured":"El-Khatib FM, Towe M, Yafi FA (2020) Management of Peyronie\u2019s disease with collagenase Clostridium histolyticum in the acute phase. World J Urol 38(2):299\u2013304. https:\/\/doi.org\/10.1007\/s00345-019-02791-x. (Epub 2019 May 15)","journal-title":"World J Urol"},{"issue":"2","key":"4975_CR53","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00345-019-02850-3","volume":"38","author":"TA Masterson","year":"2020","unstructured":"Masterson TA, Rezk A, Ramasamy R (2020) Characteristics predictive of response to collagenase clostridium histolyticum for Peyronie\u2019s disease: a review of the literature. World J Urol 38(2):279\u2013285. https:\/\/doi.org\/10.1007\/s00345-019-02850-3. (Epub 2019 Jun 26)","journal-title":"World J Urol"},{"issue":"1","key":"4975_CR54","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/s0022-5347(01)65361-8","volume":"157","author":"CJ Devine","year":"1997","unstructured":"Devine CJ, Somers KD, Jordan SG, Schlossberg SM (1997) Proposal: trauma as the cause of Peyronie\u2019s disease. J Urol 157(1):285\u2013290. https:\/\/doi.org\/10.1016\/s0022-5347(01)65361-8","journal-title":"J Urol"},{"issue":"3","key":"4975_CR55","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/path.4253","volume":"231","author":"R Kramann","year":"2013","unstructured":"Kramann R, DiRocco DP, Humphreys BD (2013) Understanding the origin, activation and regulation of matrix-producing myofibroblast for treatment of fibrotic disease. J Pathol 231(3):273\u2013289. https:\/\/doi.org\/10.1002\/path.4253","journal-title":"J Pathol"},{"issue":"1","key":"4975_CR56","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1743-6109.2011.02519.x","volume":"9","author":"MR Aber","year":"2012","unstructured":"Aber MR, Larsen S, Levine LA (2012) Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie\u2019s disease. J Sex Med 9(1):288\u2013295. https:\/\/doi.org\/10.1111\/j.1743-6109.2011.02519.x. (Epub 2011 Oct 24)","journal-title":"J Sex Med"},{"issue":"2","key":"4975_CR57","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/jsm.12400","volume":"11","author":"JI Martinez Salamanca","year":"2014","unstructured":"Martinez Salamanca JI et al (2014) Acute phase Peyronie\u2019s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med 11(2):506\u2013515. https:\/\/doi.org\/10.1111\/jsm.12400","journal-title":"J Sex Med"},{"key":"4975_CR58","first-page":"A8345","volume":"159","author":"V Dalm","year":"2015","unstructured":"Dalm V, Dik WA, Thio HB, van den Blink B, van Hagen PM, van Daele PL (2015) Fibrosing disorders: insight into pathogenesis and new treatment options. Ned Tjdschr Geneeskd 159:A8345","journal-title":"Ned Tjdschr Geneeskd"},{"key":"4975_CR59","unstructured":"European Association of Urology Sexual and Reproductive Health Guidelines. https:\/\/uroweb.org\/guidelines\/sexual-and-reproductive-health"},{"issue":"3","key":"4975_CR60","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11845-013-1036-5","volume":"183","author":"U Ozturk","year":"2014","unstructured":"Ozturk U, Yesil S, Goktug HN, Gucuk A, Tuygun C, Sener NC, Nalbant I, Imamoglu MA (2014) Effects of sildenafil treatment on patients with Peyronie\u2019s disease and erectile dysfunction. Ir J Med Sci 183(3):449\u2013453. https:\/\/doi.org\/10.1007\/s11845-013-1036-5. (Epub 2013 Nov 5. PMID: 24190613)","journal-title":"Ir J Med Sci"},{"issue":"5","key":"4975_CR61","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/j.1743-6109.2011.02217.x","volume":"8","author":"E Chung","year":"2011","unstructured":"Chung E, Deyoung L, Brock GB (2011) The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med 8(5):1472\u20131477. https:\/\/doi.org\/10.1111\/j.1743-6109.2011.02217.x. (Epub 2011 Feb 16. PMID: 21324095)","journal-title":"J Sex Med"},{"key":"4975_CR62","unstructured":"Salonia A, Bettocchi C, Carvalho J et al (2022) (EAU Sexual and Reproductive Health Guidelines Panel). European Association of Urology Sexual and Reproductive Health Guidelines; EAU Guidelines. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Sexual-and-Reproductive-Health-2022_2022-03-29-084141_megw.pdf"},{"issue":"3","key":"4975_CR63","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","volume":"194","author":"A Nehra","year":"2015","unstructured":"Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, Khera M, Kirkby E, McVary KT, Miner MM, Nelson CJ, Sadeghi-Nejad H, Seftel AD, Shindel AW, Burnett AL, American Urological Association Education and Research, Inc. (2015) Peyronie\u2019s disease: AUA guideline. J Urol 194(3):745\u2013753. https:\/\/doi.org\/10.1016\/j.juro.2015.05.098. (Epub 2015 Jun 9. PMID: 26066402; PMCID: PMC5027990)","journal-title":"J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04975-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-04975-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04975-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:30:37Z","timestamp":1735853437000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-04975-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4975"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-04975-6","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]},"assertion":[{"value":"4 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no disclosures or conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"No need.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"317"}}